Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 85,985 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Alzheimer Disease
Interventions: Donepezil, BMS-708163; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more

Conditions: Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise, Dietary Supplement
Interventions: Phaeosol group, Placebo group; Dietary Supplement
Lead sponsor: Microphyt; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Chemotherapy-induced Neutropenia
Interventions: Plinabulin, Pegfilgrastim, Saline Placebo, D5W Placebo; Drug · Other
Lead sponsor: BeyondSpring Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Stanford, California • Skokie, Illinois • Louisville, Kentucky

Conditions: Melanoma
Interventions: Talimogene laherparepvec, GM-CSF; Biological
Lead sponsor: BioVex Limited; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 57
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Distress Due to COVID-19
Interventions: Expressive writing; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions: nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Venous Thromboembolism
Interventions: Education; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Dexamethasone, Aspirin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more

Conditions: Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Interventions: Ibrutinib, DA-EPOCH-R, Lenalidomide; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Orange, California + 7 more

Conditions: Tissue and Organ Procurement
Interventions: Web intervention; Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years to 60 Years
Enrollment: 4,827 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: End Stage Renal Disease, Hemodialysis
Interventions: Alpha tocopherol; Drug
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type1 Diabetes Mellitus, Type2 Diabetes Mellitus
Interventions: HM12470; Biological
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Acquired Brain Injury
Interventions: Building Better Caregivers, Problem Solving Training, Usual Care; Behavioral
Lead sponsor: Shepherd Center, Atlanta GA; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Tick Bites, Mast Cell Activation Disorders, Tick-Borne Diseases
Interventions: Ketotifen, fexofenadine, Cromolyn Sodium; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Advanced Melanoma
Interventions: Autogene cevumeran, Pembrolizumab; Biological · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • San Francisco, California + 14 more

Conditions: Low Testosterone Levels
Interventions: Qualia Testosterone+, Placebo; Dietary Supplement · Other
Lead sponsor: Qualia Life Sciences; Industry
Eligibility: 28 Years to 65 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Lung Cancer
Interventions: cisplatin, gefitinib, gemcitabine hydrochloride; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Substance Use Disorders, Insomnia
Interventions: Cognitive Behavioral Therapy for Insomnia (CBT-I); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 25
States / cities: Mobile, Alabama • San Francisco, California • New Haven, Connecticut + 19 more

Conditions: Advanced NSCLC, Metastatic Lung Cancer
Interventions: Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin; Drug · Combination Product
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 59
States / cities: Fountain Valley, California • Fullerton, California • San Francisco, California + 45 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Indianapolis, Indiana + 6 more

Conditions: Chronic Pain, Abdominal Pain, Headache
Interventions: Problem-Solving Skills Training; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Staphylococcal Skin Infection
Interventions: Telavancin, Vancomycin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

Drug-Drug Interaction Study With Aricept® (Donepezil)

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Expressive Writing for COVID-19 Resilience

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Online Intervention for ANHPI College Students

Oxidative Stress and Hemodialysis Access Failure

Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus

Comparison of Two Interventions for Caregivers of Patients With Acquired Brain Injury

Mast Cell Treatment in Post-tick Bite Illness (PTBI)

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Efficacy of Qualia Testosterone+ on Testosterone Levels in Adult Males

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Cognitive Behavioral Therapy for Insomnia in Substance Use Disorders

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.

Problem Solving Skills Training For Parent Caregivers of Youth With Chronic Pain

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus